Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Shares Issued (2020 - 2025)

Historic Shares Issued for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $49.8 million.

  • Lyell Immunopharma's Shares Issued changed N/A to $49.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.4 million, marking a year-over-year increase of 317306.94%. This contributed to the annual value of $1.2 million for FY2024, which is 3410.77% down from last year.
  • Lyell Immunopharma's Shares Issued amounted to $49.8 million in Q3 2025.
  • Lyell Immunopharma's 5-year Shares Issued high stood at $392.0 million for Q2 2021, and its period low was -$1.1 million during Q3 2021.
  • Moreover, its 5-year median value for Shares Issued was $807500.0 (2021), whereas its average is $32.5 million.
  • Its Shares Issued has fluctuated over the past 5 years, first plummeted by 312857.14% in 2021, then surged by 58367.92% in 2022.
  • Over the past 5 years, Lyell Immunopharma's Shares Issued (Quarter) stood at -$1.1 million in 2021, then skyrocketed by 130.66% to $325000.0 in 2022, then soared by 124.92% to $731000.0 in 2023, then crashed by 40.08% to $438000.0 in 2024, then skyrocketed by 11273.52% to $49.8 million in 2025.
  • Its Shares Issued stands at $49.8 million for Q3 2025, versus $184000.0 for Q2 2025 and $438000.0 for Q4 2024.